- Enzo Biochem Inc ENZ has received an expansion of its FDA Emergency Use Authorization (EUA) for its rapid extraction method on its Ampiprobe SARS-CoV-2 Test System to detect SARS-CoV-2, including the variants.
- The EUA enables laboratories to immediately use Enzo's faster extraction process to reduce the time by over one hour, or more than 25%, allowing more test runs on a single instrument.
- Price Action: ENZ shares are up 11.70 at $3.43 during the premarket session on the last check Tuesday.
ENZEnzo Biochem Inc
$0.3230-0.31%
Edge Rankings
Momentum
3.00
Growth
0.46
Quality
-
Value
92.19
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
